U.S. trade partners are buying up more American goods and trying to curry favor with president Donald Trump in an effort to stave off sweeping tariffs.The administration is negotiating with more than ...

Ipsen and its fellow French partner Genfit are competing with Intercept and Advanz’s Ocaliva, which was approved in 2016 and ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

Vaughn College of Aeronautics and Technology has received federal approval to launch a new, accelerated air traffic controller training program ...

Ensuring timely completion of post-approval studies and enforcing appropriate regulatory actions based on negative trial results is necessary to minimize patient exposure to ineffective and ...

OS Therapies (OSTX) announced that it has submitted a request for a formal meeting with the Center for Biologics Evaluation and Research of the ...

Amvuttra Gains Approval for Transthyretin Amyloid Cardiomyopathy Arbli (losartan potassium oral suspension) Angiotensin II receptor blocker For the treatment of hypertension, to lower blood ...

Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...

FDA grants accelerated approval for Novartis's Vanrafia (atrasentan) for IgA nephropathy. The drug joins Tarpeyo and Filspari as well as Novartis' own Fabhalta in treating this rare kidney disease.

FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support ...